|
Author, year | Country | Study period | No. of patients | Median age, years (range) | Gender (males, %) | Ethnicity (%) | Smokers (%) | Clinical stage (%) | Median follow-up in months | TKI (dose) | Additional therapy |
|
Han et al., 2007 [55] | Korea | Jan 2002–Dec 2004 | 86 | 61 (30–87) | 57.0 | NR | 55.8 | IIIB (5.8); IV (94.2) | 16.9 | Gefitinib (250 mg/d) | NR |
|
Ichihara et al., 2007 [26] | Japan | Nov 2000–May 2006 | 98 | 66 (NR) | 63.0 | NR | 62.0 | NRb | 11.4c | Gefitinib (250 mg/d) | 88.0% of patients previously treated with chemotherapy |
|
Liu et al., 2008 [56] | USA and Canada | Dec 2000–Feb 2003 | 92 | 61 (36–87) | 41.0 | Caucasian (95); Asian (3); African American (2) | 79.0 | IIIB (7.0); IV (93.0) | 28.5 (PFS); 29.9 (OS) | Gefitinib (NR) | 85.0% of patients were previously, and 95% concurrently treated with chemotherapy |
|
Giovannetti et al., 2010 [57] | Italy | NR | 96 | 64 (NR) | 57.3 | NR | 68.8 | IIIB (9.4); IV (90.6) | NR | Gefitinib (250 mg/d) | 84.5% of patients were previously treated with chemotherapyd |
|
Tiseo et al., 2010 [58] | Italy | NR | 91 | 67 (40–85) | 61.5 | Caucasian (100) | 78.0 | III (11.0); IV (89.0) | NR | Gefitinib (250 mg/d) | All patients were previously treated with chemotherapy |
|
Nie et al., 2011 [60] | China | Jun 2002–Sep 2006–Jul 2010a | 115e | 57 (NR) | 56.5 | NR | NR | IV (83.5) | 54.0 | Gefitinib (250 mg/d) or erlotinib (150 mg/d) | All patients were previously treated with chemotherapy |
|
Jung et al., 2012 [25] | Korea | Jan 2007–Dec 2010 | 71f | 59 (34–85) | 62.0 | Asian (100) | 57.7 | NR | 12.7 | Gefitinib (250 mg/d) or erlotinib (150 mg/d) | All patients were previously treated with chemotherapy |
|
Zhang et al., 2013 [31] | China | Jan 2008–Dec 2010 | 128 | 55 (32–80) | 48.4 | NR | 32.0 | IIIB (25.0); IV (75.0) | 16.6 | Gefitinib (250 mg/d) | All patients were previously treated with one or two other therapy options |
|
Winther-Larsen et al., 2014 [59] | Denmark | Jan 2007–Oct 2011 | 62g | 65 (33–88) | 40.0 | Caucasian (100) | 16.0 | IV (100) | 52.2 | Erlotinib (150 mg/d, dose reduced in case of side effects grade 2 or higher) | NR |
|
Winther-Larsen et al., 2015 [32] | Denmark | Jan 2007–Apr 2014 | 331 | 64 (34–89) | 46.0 | Caucasian (100) | 26.0 | IV (100) | 62.7 | Erlotinib (150 mg/d, dose reduced in case of side effects grade 2 or higher) | 84.0% and 10% of patients were previously treated with platinum-based and pemetrexed and/or docetacel-based chemotherapy, respectively |
|
Kim et al., 2017 [61] | Italy and Canada | NR | 760 | 62 (27–81) | 66.3 | East Asian (3.2); other (96.8) | 79.3 | IIIB (10.9); IV (89.1) | 36.0 | Erlotinib (150 mg/d) | 50% of patients were treated with erlotinib, followed by cisplatin and gemcitabine at progression; other 50% were treated with cisplatin and gemcitabine, followed by erlotinib at progression |
|